Ministry of Education to treat exempted students as 'immune'    Riyadh Season 2 kicks off on Oct. 20    Organizations in Saudi Arabia view data overload as prime barrier to transformation    Solar power's supply chain crisis makes 1.5°C climate target a major challenge    50 firms collaborate to champion Next Gen careers in industry    Biden: Bilateral ties with India is destined to be 'stronger, closer and tighter'    Ash cloud from La Palma volcano causes closure of airport    China frees two Canadians after Huawei CFO flies home, ending diplomatic row    Expat arrested for harassing women in Jeddah    Saudi Arabia seeks to develop relations with all countries: FM    Saudi Arabia arrests 15,693 illegals in a week    Saudi music legend Mohamed Abdo to perform at Expo 2020's opening ceremony    Afghanistan: Girls' education must be a given, urges deputy UN chief    SAMF achieves world record for largest brick built F1 car    Saudi Automobile and Motorcycle Federation unveils largest Formula 1 car model    EU proposes common charger for electronic devices    Saudis, expats mourn death of prominent Filipino preacher in Riyadh    Sex and the City star Willie Garson dies aged 57    Saudi Arabia observes Alzheimer's Day with rest of world    Al Burj, Chinar, CSG, Kashmir Stags, ARM, Pak Zalmi record big wins in Kanoo League    Saudi International, Asian Tour confirm historic partnership    Bollywood actor Sidharth Shukla dies at 40    Custodian of the Two Holy Mosques Directs KSrelief to Urgently Provide Malaysia with Medical, Preventive Equipment and Supplies to Address COVID-19 Pandemic    Custodian of the Two Holy Mosques Congratulates President of Maldives on Independence Day    Weather Forecast for Sunday    RSNF Commander Patronizes Ceremonial Launching of His Majesty's Ship "Jazan"    OIC Condemns Houthi Attempts to Target Civilians in Saudi Arabia    Philippines evacuates thousands as monsoon rains flood cities, provinces    Heavy rain in India triggers floods, landslides; at least 125 dead    U.S. Records 64,321 New Infections of Coronavirus    Without Fans, Tokyo Olympics Kicked Off    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Dr. Mohammed Sulaiman Al-Jasser, Saudi Arabia's Pick to Chair IsDB Group for the next five years, unanimously approved by BoG Committee of Procedures    Saudi Press: Fitch affirms Saudi Credit Rating at "A" with a revised outlook to stable from negative    Handled Cargo at Saudi Ports Increases during June 2021    SDAIA, DARP & STC Launch Pilgrim's Smart Bracelet (NUSK)    Tabuk sculptor spends 8 years in carving entire Holy Qur'an on 30 marble slabs    2 Goals by Diaz Gives Colombia 3rd Place at Copa America    Legendary actor Dilip Kumar, 98, passes away, and with him an era    Saudi Cinema Night at Arab World Institute in Paris Kicks Off    KSU Leads Joint International Scientific Project for Early Detection of Breast Cancer    Saudi Arabia to Participate in Cannes Film Festival 2021    Arab Cup U-17 Championship Draw Saudi Arabia, Morocco, Palestine, Kuwait, in the 1st Group    AWI Hosts Saudi Cinema Nights in Paris    Brazil Beats Chile at Copa America Despite 2nd-Half Red Card    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Avid CEO confident in Alzheimer's imaging agent
Published in Saudi Press Agency on 16 - 07 - 2011

The chief executive of Eli Lilly and Co's Alzheimer's imaging unit is confident it can create a training program for its imaging drug that will satisfy concerns raised by U.S. regulators, according to Reuters.
So are many Alzheimer's disease experts, who are gathering in Paris this week for the Alzheimer's Association's international conference.
Imaging the clumps of a toxic protein called beta amyloid that accumulate in the brains of patients with Alzheimer's is seen as a critical step toward identifying the disease in the earlier stages, before memory problems begin.
Researchers increasingly believe this is the best time to intervene with drugs that might delay or prevent the disease from progressing.
Lilly is seeking U.S. Food and Drug Administration approval to market the agent, a radioactive tracer called Amyvid, for use with positron emission tomography, or PET, scans to help doctors rule out the plaque linked with Alzheimer's.
In January, an advisory panel to the FDA unanimously said Amyvid appears to detect brain plaques associated with the memory disease, but that more data is needed to show the scans can be properly interpreted.
"Since we got that feedback, we're working with the FDA to figure out what is required," said Dr. Daniel Skovronsky, president and CEO of Avid Radiopharmaceuticals, a wholly owned unit of Lilly.
"We're quite confident that we will be successful," Skovronsky said in a telephone interview ahead of the conference, which runs July 16-21.
He said data from the company's clinical trials was convincing, but the FDA said the test was too complicated for clinical use and may lead to inconsistent readings.
So the company is trying to focus its training on answering a simple question: "Is there amyloid in the brain? Yes or no?" Skovronsky said.
He said the FDA will not require additional clinical trials involving patients.
"I expect ultimately it will win approval," said Dr. Michael Weiner, who is leading the Alzheimer's Disease Neuroimaging Initiative, a federal study that uses imaging and other tests to track the progress of Alzheimer's over time.
"I think most people see this as a temporary problem," said Weiner, who also directs the Center for Imaging of Neurodegenerative Disease at the Veterans Affairs Medical Center in San Francisco.
If approved, the test will tell doctors whether amyloid is gathering in the brain. If there is none, it would tell doctors to look for other causes of mental decline, such as depression or medications.
"I've talked to some scientists who feel these scans can help them in assessing their patients," Weiner said, adding: "Once there are treatments, these tests are going to be much more important."
Avid's compound is already being widely used by various drug companies in clinical trials, and Lilly's $800 million acquisition of Avid last November raised concerns among Lilly's rivals.
"One of the early questions on everyone's mind was, 'Are you going to continue to collaborate with us even though we are developing a drug that might compete with a Lilly drug?'"
"The answer right from the outset was yes," Skovronsky said. "We are committed to this open collaboration model."
Avid has been ahead in the race for such imaging agents that are estimated to have a potential global market anywhere from $1 billion to $5 billion.
General Electric Co and Bayer AG are also developing rival products, but Avid's delay at the FDA may have cost the company some of its lead.
"When you are first, you are developing a path that others will follow. That is the benefit but also the cost of being in the lead," Skovronsky said.


Clic here to read the story from its source.